z-logo
open-access-imgOpen Access
Depletion of multidrug‐resistant uropathogenic Escherichia coli BC1 by ebselen and silver ion
Author(s) -
Wang Peng,
Wang Jun,
Xie Zonglan,
Zhou Jingxuan,
Lu Qianqian,
Zhao Ying,
Dong Chuanjiang,
Zou Lili
Publication year - 2020
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.15920
Subject(s) - escherichia coli , ebselen , multiple drug resistance , microbiology and biotechnology , chemistry , biology , drug resistance , biochemistry , gene , enzyme , glutathione , glutathione peroxidase
Ebselen, an organo‐selenium compound with well‐characterized toxicology and pharmacology, recently exhibited potent antibacterial activity against glutathione (GSH)‐negative bacteria by disrupting redox homeostasis. In this paper, we show that ebselen and silver ion in combination exert strong bactericidal activity against multidrug‐resistant (MDR) uropathogenic Escherichia coli (UPEC) BC1, a model MDR GSH‐positive bacterium. The mechanisms were found to involve consumption of total intracellular GSH and inhibition of thioredoxin reductase activity, which was highly related to reactive oxygen species up‐regulation. Furthermore, the therapeutic efficacy of ebselen and silver ion against UPEC‐induced cystitis was assessed in a mouse model. Treatment with ebselen and silver ion significantly reduced bacterial loads, down‐regulated the expression levels of tumour necrosis factor‐α (TNF‐α) and interferon‐γ (IFN‐γ) on‐site and decreased white/red blood cell counts in mild cystitis model mice, which demonstrated the anti‐inflammatory property of these agents. In addition, ebselen and silver ion also exhibited significantly high protective ability (100%) against acute cystitis infections. These results together may lay the foundation for further analysis and development of ebselen and silver ion as antibacterial agents for treatment of MDR UPEC infections.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here